The Big Picture: The current and evolving HIV prevention landscape

Similar documents
The Big Picture: The current and evolving HIV prevention landscape

The Open Label Trial Past and Present

The Open Label Trial Past and Present

The HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE

Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012

Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel

Understanding the Results of VOICE

Using anti-hiv drugs for prevention

What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women

HIV Prevention Strategies HIV Pre-exposure prophylaxis

The HIV Prevention Pill: The State of PrEP Science and Implementation

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention

MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

Where are we going after effectiveness studies?

Overview of ARV-based prevention trials

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

Update on PrEP progress: WHO/UNAIDS challenges and actions

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials:

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D.

Biomedical Prevention Update Thomas C. Quinn, M.D.

Update on ARV based PrEP

Update on Antiretroviral-Based HIV Prevention

Mucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials. Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA

On the Horizon for Consideration: Biomedical Advances in HIV Prevention

Where We Have Been and Where We are Going. Ian McGowan MD PhD FRCP

Review of planned trials and key emerging issues for Thailand

Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:

ARVs for prevention in at-risk populations: Microbicides

TasP - Individual versus Public Health Benefit versus Both.

Novel HIV Prevention Methods for Women

8/25/2016. Making Preexposure Prophylaxis Available in the Clinic: Considerations and Pathways Forward

International Partnership for Microbicides

WOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society

Strategic use of antiretroviral drugs to prevent HIV transmission

Biomedical Prevention in HIV

A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)

Drug development in relation to PrEP and the PROUD study

ART and Prevention: What do we know?

Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments

Pre-exposure Prophylaxis (PrEP)

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.

ART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK

Combination prevention: Public health and human rights imperatives

An Update on the HIV Prevention Landscape: The Role of Combination Prevention

Multiple choice questions: ANSWERS

PEP and PrEP: AWAAC 2014

BLT mice in HIV prophylaxis

Translating the Science to End New HIV Infections in Kenya

10/05/2016. PrEP : from proof of concept to real life. E. CUA Nice university hospital

Antiretrovirals for HIV prevention:

PEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital

Doing studies of ARV based

11/8/2016. Moving Beyond Truvada: The (Current) Future Pipeline for PrEP. Prevention Modalities

International Partnership for Microbicides

Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location

The HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018

Pre-exposure prophylaxis (PrEP)

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

Psychosocial Issues in ART and HIV Prevention. Steven A. Safren, PhD

Combination HIV Prevention

Can we treat our way out of the HIV epidemic?

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program

PrEP Dosing Strategies

PrEP: Pre Exposure Prophylaxis

Evolving HIV Treatment Paradigms What we need to know

What Is the Dapivirine Ring?

Clinical and Public Health Policy Implications of Findings that:

Welcome and State of the Network. Cape Town, South Africa 27 th September 2016

Understanding the Impact of an HIV Intervention Package for Adolescents

MTN 2018 State of the Network

What s in the Biomedical Prevention Pipeline

Direct from Delhi: Microbicides2008 Comes to Sweet Home Chicago

Dominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis

Antiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies

PrEP Guidelines for the Ob/Gyn. Outline. 1. How many patient have you discussed PrEP with this year?

ASPIRE Overview Where we are today

Getting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day

Adolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa. Jessica Haberer, MD, MS November 9, 2017

PREPARING FOR PREP: FROM KEY POPULATIONS THEORY TO PRACTICE. Dr Oscar Radebe

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

PrEP May Cause a Revolution in HIV Prevention: Time to Get Ready

MTN 2011 Annual Meeting Arlington, VA. The Microbicide Pipeline: A Critical Review. J. Romano March 29, 2011

QUESTIONS AND ANSWERS

Treatment as Prevention in India: What will it take?

QUESTIONS AND ANSWERS

Successful results of clinical trials

A Field on the Verge of Change

Pre-exposure Prophylaxis and Primary Care

PrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.

HIV Prevention among Women

HIV Prevention: 2010

MTN 034/IPM 045: REACH Rings and PrEP in Young Women

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

Understanding the results of CAPRISA 004

Microbicides and Antiretroviral Therapy

Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection

FHI Study 10015: FEM-PrEP

Transcription:

The Big Picture: The current and evolving HIV prevention landscape Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking stakeholder perspectives on next steps with the for HIV prevention in women 6 August 2014, Lilongwe

Overview 2010-2014 Rapid Recap Lessons learned 2014-2018 Fast Forecast Opportunities in the offing

The HIV Prevention Timeline 2010-2014 HPTN 052 results TasP in serodiscordant couples (May 2011) iprex results Truvada in MSM (Nov 2010) Partners PrEP Truvada and tenofovir in serodiscordant couples (July 2011) CDC TDF2 Truvada in men and women (July 2011) FDA approval of Truvada for prevention (July 2012) The Ring Study starts April 2012 ASPIRE starts August 2012 Pop-ART (HPTN 071) starts Test and Treat/TasP (Nov 2013) Bangkok tenofovir study (in IDUs) results (June 2013) CAPRISA 004 results tenofovir gel (July 2010) FACTS 001 starts tenofovir gel (Oct 2011) CAPRISA 008 starts Tenofovir gel Nov 2012 HVTN 097 starts vaccine (June 2013) 2010 2011 2012 2013 2014 FEM-PrEP stops Truvada in women (April 2011) VOICE stops tenofovir arm (in women) (Sept 2011) VOICE stops tenofovir gel (in women) (Nov 2011) VOICE results tenofovir gel, Truvada, tenofovir (in women) (March 2013) HVTN 505 stops vaccine (May 2013)

2010-2014: Rapid Recap A time to celebrate: The first proof of concept for a vaginal microbicide (CAPRISA 004) The first proof of concept for oral PrEP (iprex), i.e., a daily pill FDA approval of Truvada based on iprex and Partners PrEP HPTN 052 and TasP Breakthrough of the Year A time to reflect: Two studies (FEM-PrEP and VOICE) no product was effective for HIV prevention women didn t use them A vaccine didn t work to prevent HIV (HVTN 505) A time to look ahead: Start of FACTS 001 trial of tenofovir gel aiming to replicate CAPRISA 004 results A new product (dapivirine vaginal ring) enters Phase III trials

The HIV Prevention Landscape 2014 2018? Ongoing PrEP demonstration projects Pop-ART (HPTN 071) Test and Treat/TasP (continues) MCC approval of Truvada for PrEP?? FACTS 001 results tenofovir gel (early 2015) CAPRISA 008 results Tenofovir gel (2015) Series of HVTN vaccine trials begins?? The Ring Study results (2016) ASPIRE results (early 2016) Tenofovir gel approval?? Ring Study openlabel trial? (2016?) MTN-025 ASPIRE open-label trial?? (mid 2016?) Rectal microbicide Phase III trial? (reduced glycerin tenofovir gel) (2016)?? Dapivirine ring approval?? Vaccine efficacy trials?? 2014 2015 2016 2017 2018

2014-2018: Fast Forecast???? Tenofovir gel Results of FACTS-001 Possible regulatory approval? Dapivirine ring Results of ASPIRE Results of The Ring Study Possible regulatory approval? PrEP and TasP Approval of Truvada for prevention? Introduction? Increased emphasis on earlier treatment for prevention New approaches, new trials The start of large trials of new vaccines? Rectal microbicide in Phase III trial? Long-acting injectables in Phase II trials? Combined ARV/contraceptive ring?

Developing a range of options for women Pill Ultimate goals: Gel Vaginal ring Vaginal film Products that are long-acting, safe, effective, low-cost and user-friendly Multiple options - maximize choice & optimize effectiveness Finding products that work is not enough - need to develop HIV prevention approaches that also are: Less stigmatizing Can be incorporated into daily life Are desirable to the people who need them Injectable

Thank you